CMRXCHIMERIX INC

Nasdaq chimerix.com


$ 0.96 $ -0.02 (-2.04 %)    

Monday, 26-Aug-2024 10:42:01 EDT
QQQ $ 475.70 $ -4.23 (-0.88 %)
DIA $ 412.95 $ 0.10 (0.03 %)
SPY $ 560.57 $ -2.62 (-0.47 %)
TLT $ 98.32 $ -0.33 (-0.33 %)
GLD $ 232.25 $ -1.23 (-0.53 %)
$ 0.98
$ 0.97
$ 0.95 x 200
$ 0.96 x 200
$ 0.96 - $ 0.99
$ 0.75 - $ 1.30
795,407
na
87.85M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-02-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-02-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-25-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-05-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 03-01-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-02-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-05-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-06-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-member-states-information-sessio...

Core News & Articles

https://www.fox2detroit.com/news/mpox-wayne-county-health-department-confirms-first-case-since-2022?taid=66c643be103e400001efc3...

Core News & Articles

- Reuters 

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 hc-wainwright--co-reiterates-buy-on-chimerix-maintains-11-price-target

HC Wainwright & Co. analyst Edward White reiterates Chimerix (NASDAQ:CMRX) with a Buy and maintains $11 price target.

Core News & Articles

- Reuters

Core News & Articles

https://x.com/i/broadcasts/1kvJpbgRNWgKE

Core News & Articles

https://x.com/i/broadcasts/1kvJpbgRNWgKE

 chimerix-q2-2024-gaap-eps-023-inline-sales-129000k-beat-62500k-estimate

Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 9.52 ...

Core News & Articles

- Bloomberg

Core News & Articles

https://www.axios.com/2024/08/05/mpox-who-warning-africaThe World Health Organization is weighing discussions on whether to dec...

 chimerix-expects-dordaviprone-interim-overall-survival-data-in-2025-and-final-os-data-in-2026

Dordaviprone is an oral, first-in-class small molecule imipridone that selectively binds to the G-protein coupled dopamine rece...

 chimerix-q1-2024-gaap-eps-025-misses-021-estimate

Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by...

Core News & Articles

https://twitter.com/DrTedros/status/1778423967105139108  

 hc-wainwright--co-reiterates-buy-on-chimerix-maintains-11-price-target

HC Wainwright & Co. analyst Edward White reiterates Chimerix (NASDAQ:CMRX) with a Buy and maintains $11 price target.

 chimerix-q4-eps-020-beats-024-estimate-sales-400k-miss-6000k-estimate

Chimerix (NASDAQ:CMRX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 1...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION